AMENDMENT TO LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT, and Commercialization Agreement • March 3rd, 2020 • Prothena Corp PLC • Pharmaceutical preparations
This AMENDMENT TO LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT (the “Amendment”) is made effective June 6, 2018 (the “Amendment Effective Date”) hereby amends the and is to the LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT (the “Agreement”) December 11, 2013 by and between NEOTOPE BIOSCIENCES LIMITED (as of January 5, 2015 PROTHENA BIOSCIENCES LIMITED, “Prothena Ireland”) with respect to all rights and obligations under this Agreement outside of the United States, and PROTHENA BIOSCIENCES INC. (“Prothena US”) with respect to all rights and obligations under this Agreement in the United States (Prothena US, together with Prothena Ireland, “Prothena”), on the one hand, and F. HOFFMANN-LA ROCHE LTD (“Roche Basel”) with respect to all rights and obligations under this Agreement outside of the United States, and HOFFMANN-LA ROCHE INC. (“Roche Nutley”) with respect to all rights and obligations under this Agreement in the United States (Roche Nutley, together with Roche Base
RELEASE AGREEMENTRelease Agreement • March 3rd, 2020 • Prothena Corp PLC • Pharmaceutical preparations • California
This Release Agreement (this “Agreement”) by and between A.W. Homan (“Executive”) and Prothena Biosciences Inc, a Delaware corporation (the “Company”) is made effective as of the eighth day following the date that the Company and Executive sign this Agreement (the “Effective Date”), with reference to the following facts:
Attorney [address redacted]Prothena Corp PLC • March 3rd, 2020 • Pharmaceutical preparations
